HOME : Support : Dialog Search Aids : Bluesheets
RSS FeedAdd RSS | What is RSS?
View Bluesheets by | Database Name | File Number | Subject | OneSearch Categories | Search Options |
461
USP DI® Volume I, Drug Information for the Health Care Professional

Last Loaded on Web: Thursday, May 01, 2008

Last Update To Bluesheet: March 16, 2004

Bluesheet Contents     PDF version

File Description Dialog File Data Special Features Sample Record Sort Rates
Subject Coverage Database Content DIALINDEX/OneSearch Categories Basic Index Rank
Tips Document Types Indexed Contact Additional Indexes Map
Print Counterparts Geographic Coverage Terms and Conditions Limit Predefined Format Options


File Description [top]

The USP DI® Volume I, Drug Information for the Health Care Professional database is a complete, unbiased source of drug information. It contains medically accepted uses for generic and brand name drug products. File 461 contains more than 800 monographs covering more than 11,000 generic and brand name drugs, grouped by family where appropriate. USP DI is named in federal, and some state, statutes as a resource for unlabeled drug uses, patient consultation, and development of drug utilization review (DUR) criteria under Medicaid.

The information in the USP DI® Volume I database undergoes an approval process unmatched by any other drug information resource. It is the result of the consensus of 35 expert advisory panels representing medicine, dentistry, nursing, and pharmacy; and scientific, professional, consumer, and trade organizations. More than 800 volunteers who serve on USP's committees and panels review information before it is incorporated into the database, ensuring that it is complete, unbiased, and as free from commercial conflict as possible.



Tips [top]

USE FILE 461

to monitor generic and brand name drug products, patient consultation, and DUR criteria.

USE MAP

to locate CAS® Registry Numbers in other databases, e.g., MAP NA TEMP.

USE RANK

S CL=CV?

RANK SH S1 CONT



Subject Coverage [top]

Each monograph includes these important sections:

  • Category (including indications)
  • Medically Accepted Labeled and Unlabeled Uses
  • Drug Interactions and Other Precautions
  • Pharmacology/Pharmacokinetics
  • Side/Adverse Effects
  • Patient Consultation
  • Dosing Information
  • Dosage Form


Print Counterparts [top]

  • USP DI Volume I


Dialog File Data [top]

Dates Covered: Same as current edition
File Size: 1,236 monographs (covering more than 10,000 generic and brand name drugs)
Update Frequency: Quarterly


Database Content [top]

  • Complete Text Records


Document Types Indexed [top]

  • Books and Monographs


Geographic Coverage [top]

  • US Only


Geographic Restrictions [top]

  • None


Special Features [top]

  • ERA Available
  • Graduate Education Program
  • KWIC and HILIGHT Available
  • MAP Available


DialIndex/OneSearch Categories [top]

ACRONYM CATEGORY NAME
BRANDNMS Brand Names
DRUGDIR Drug Directories
PHARMR Pharmacology + RINGDOC-Files
SAFETY Safety
TOXICOL Toxicology


Contact [top]

USP DI® Volume I, Drug Information for the Health Care Professional is developed by Thomson MICROMEDEX. Questions concerning file content should be directed to:

Thomson MICROMEDEX
6200 South Syracuse Way, Suite 300
Greenwood Village, CO 80111-4740

Telephone: 303-486-6400
800 Line: 800-525-9083
Fax: 303-486-6464
E-Mail: mdx.info@thomson.com


Terms and Conditions [top]

USP DI is a registered trademark of The United States Pharmacopeial Convention, Inc (USP) used under license to Thomson Healthcare Inc.

TERMS AND CONDITIONS: USP DI(r) is a registered trademark of the United States Pharmacopeial Convention (USP) used under license to Thomson Healthcare, Inc. "For Dialog's Redistribution and Archive Policy, enter HELP ERA online. The following terms and conditions also apply.

Customer shall not store in machine-readable form, and shall not sell, assign, license, transfer, or transmit to any third party, any portion of the Databases, on either a permanent or temporary basis.

Unless Customer subscribes to the DIALOG ERASM(Electronic Redistribution and Archiving) Service, Customer may create only one printed copy of search results for Customer's personal use, provided that Customer immediately destroys the machine-readable search results upon creation of the printed version. Printed copies of search results may contain only insubstantial portions of a Database. Customer shall obtain Thomson Healthcare's written permission for any other use or reproduction of the Databases.

The information contained in the Thomson Healthcare products is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. All treatments or procedures are intended to serve as performing the consultation or evaluation of patients and must be interpreted in view of all attendant circumstances, indications, and contraindications. Talk to your doctor, nurse, or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.

The use of the Thomson Healthcare products is at you sole risk. These products are provided "as is" and "as available" for use, without warranties of any kind, either express or implied. THOMSON HEALTHCARE MAKES NO REPRESENTATION OR WARRANTY AS TO THE ACCURACY, RELIABILITY, TIMELINESS, USEFULLNESS OR COMPLETENESS OF ANY OF THE INFORMATION CONTAINED IN THE PRODUCTS. ADDITIONALLY, THOMSON HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD, OR USE AS A RESULT OF THE USE OF THE THOMSON HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. THOMSON HEALTHCARE DOES NOT ASSUME ANY RESPONSIBILITY OR RISK FOR YOUR USE OF THE THOMSON HEALTHCARE PRODUCTS."
Dialog Standard Terms & Conditions apply.


SAMPLE RECORD [top]

    DIALOG(R)File 461:USP DI(R) Vol. I 
     (c) 2004 Thomson Healthcare, Inc. All rts. reserv. 
     
     00001091 
  /TI   BETA-ADRENERGIC BLOCKING AGENTS AND THIAZIDE  DIURETICS  (Systemic) 
     
  /NA, NA=   This monograph includes information on the following: 
        Atenolol and Chlorthalidone; Bisoprolol and 
        Hydrochlorothiazide (Not commercially available in 
        Canada.); Metoprolol and Hydrochlorothiazide (Not 
        commercially available in Canada.); Nadolol and 
        Bendroflumethiazide; Pindolol and Hydrochlorothiazide (Not 
        commercially available in the U.S.); Propranolol and 
        Hydrochlorothiazide; Timolol and Hydrochlorothiazide. 
     
     Brand names: 
     
  /TN, TN=, /NA, NA=   //Corzide//[Nadolol and Bendroflumethiazide] 
     //Inderide//[Propranolol and Hydrochlorothiazide] 
     //Inderide LA//[Propranolol and Hydrochlorothiazide] 
     //Lopressor HCT//[Metoprolol and Hydrochlorothiazide] 
     //Tenoretic//[Atenolol and Chlorthalidone] 
     //Timolide//[Timolol and Hydrochlorothiazide] 
     //Viskazide//[Pindolol and Hydrochlorothiazide] 
     //Ziac//[Bisoprolol and Hydrochlorothiazide] 
     
     Note: For a listing of dosage forms and brand names by country 
           availability, see Dosage Forms section(s). 
     
  /CL, CL=   CLASSIFICATION (Primary/Secondary): CV400/CV490 
     
  /TC   CATEGORY:  Antihypertensive. 
     
     Indications 
     
     Accepted 
     Hypertension (treatment) -- Beta-adrenergic blocking agent 
        (beta-blocker) and thiazide diuretic combinations are 
        indicated in the management of hypertension. 
     
        Fixed-dosage combinations generally are not recommended 
        for initial therapy, but are utilized in maintenance 
        after the required dose is established, in order to 
        increase convenience, economy, and patient compliance. 
        For additional information on initial therapeutic 
        guidelines related to the treatment of hypertension, 
        see //Appendix III.// 
     
  /PH   PHARMACOLOGY/PHARMACOKINETICS 
     Physicochemical characteristics: 
        Molecular weight -- 
           Atenolol: 266.34. 
           Bisoprolol fumarate: 766.97. 
           Bendroflumethiazide: 421.41. 
           Chlorthalidone: 338.76. 
           Hydrochlorothiazide: 297.73. 
           Metoprolol tartrate: 684.82. 
           Nadolol: 309.40. 
           Pindolol: 248.32. 
           Propranolol hydrochloride: 295.81. 
           Timolol maleate: 432.49. 
                         (...) 
  /PS   PRECAUTIONS TO CONSIDER 
     
     Note: In general, because of the similarity of effect and 
           because the cardioselectivity of beta-1 blockers is 
           relative, the same precautions, especially drug 
           interactions and medical problems, apply to all beta- 
           adrenergic blocking agents. 
     
     Cross-sensitivity and/or related problems 
     Patients sensitive to other sulfonamide-type medications, 
        bumetanide, furosemide, or carbonic anhydrase inhibitors 
        may be sensitive to thiazide diuretics also. 
                         (...) 
  /AE   SIDE/ADVERSE EFFECTS 
     
     Note: Signs and symptoms of overdose may include sudden 
           bradycardia, hypotension, bronchospasm, cardiac 
           failure, peripheral cyanosis, and seizures; 
           hypoglycemia may occur rarely. In contrast, pindolol 
           overdose may result in tachycardia and hypertension 
           because of intrinsic sympathomimetic activity (ISA). 
           Signs of overdose usually occur within 1 to 2 hours of 
           ingestion. 
                         (...) 
  /PC   PATIENT CONSULTATION 
     As an aid to patient consultation, refer to //Advice 
        for the Patient, Beta-adrenergic Blocking Agents and 
        Thiazide Diuretics (Systemic).// 
     In providing consultation, consider emphasizing the 
        following selected information (>> (=) major clinical 
        significance): 
     
     Before using this medication 
     
     >> Conditions affecting use, especially: 
     
           Sensitivity to the beta-adrenergic blocking agent 
              prescribed, or to any thiazide diuretic or other 
              sulfonamide-type medications 
                         (...) 
  /DO   GENERAL DOSING INFORMATION 
     Fixed-dosage combinations generally are not recommended 
        for initial therapy, but are utilized in maintenance 
        therapy, after the required dose is established, in 
        order to increase convenience, economy, and patient 
        compliance. 
     
     The lowest effective dosage of thiazide diuretics 
        should be utilized to minimize potential electrolyte 
        imbalance and the reflex increase in renin and 
        aldosterone levels. 
     
     Although plasma concentrations of beta-adrenergic 
        blocking agents can be ascertained, there is not always 
        a predictable relationship between plasma concentration 
        and pharmacologic effects.  Pharmacologic effects have 
        been observed when plasma concentrations were not 
        discernible.  Therefore, titration of dosage with 
        measurement of heart rate and blood pressure is used to 
        guide therapy. 
                         (...) 
     Selected Bibliography 
     The fifth report of the Joint National Committee on 
        Detection, Evaluation, and Treatment of High Blood 
        Pressure (JNC V) 
        Arch Intern Med 1993; 153(2): 154-83. 


BASIC INDEX [top]

SEARCH
SUFFIX		 DISPLAY
CODE		 FIELD NAME
 INDEXING
 SELECT EXAMPLES
None None All Basic Index Fields Word S BETA(W)ADRENERGIC
/AE AE Side/Adverse Effects Section Word S BRONCHOSPASM/AE
/CC CC Controlled Substance Classification Section Word S SCHEDULE(W)IV/CC
/CL CL VA Classification Section1 Word S CV100/CL
/DO DO General Dosing Section Word S ORAL(S)TWO(W)TIMES/DO
/NA NA Drug Name1,2 Word S LOPRESSOR/NA
/PC PC Patient Consultation Section Word S HYPOGLYCEMIA/PC
/PH PH Pharmacology Section Word S LIPOPHILIC/PH
/PP PP Physical Properties Section Word S GAMMA(W)18/PP
/PS PS Precautions to Consider Section Word S CARBONIC(W)ANHYDRASE/PS
/TC TC Category Section Word S ANTIHYPERTENSIVE/TC
/TI TI Title3 Word S BETA(W)ADRENERGIC/TI
/TN TN Brand Name1,3 Word S NADOLOL/TN

1 Searchable in the Basic Index and in the Additional Indexes.

2 Includes brand name (/TN and TN=).

3 Also searchable as NA.


ADDITIONAL INDEXES [top]

SEARCH
PREFIX		 DISPLAY
CODE		 FIELD NAME
 INDEXING
 SELECT EXAMPLES
None AZ DIALOG Accession Number
CL= CL VA Classification Code1 Phrase S CL=CV400
NA= NA Drug Name1,2 Word
& Phrase		 S NA=PROPRANOLOL
S NA=ALKA BUTAZOLIDIN
SH= None Section Heading Phrase S SH=PHARMACOLOGY
TN= TN Brand Name1,3 Word
& Phrase		 S TN=INDERIDE
S TN=INDERIDE LA
UD= None Update Phrase S UD=9999


LIMIT [top]

Sets and terms can be limited by Basic Index suffixes, i.e., /AE, /CC, /CL, /DO, /DP, /NA, /PC, /PH, /PP, /PS,/TC, /TI, and /TN (e.g., SELECT S2/TI), as well as by the following feature:


SORT [top]

SORTABLE FIELDS EXAMPLES
TI SORT S1/ALL/TI
PRINT S5/5/1-24/TI


RANK [top]

RANK FIELDS EXAMPLES
All phrase- and numeric-indexed fields in the Additional Indexes can be ranked. RANK TN
RANK SH S4


MAP [top]

MAP FIELDS EXAMPLES
NA MAP NA TEMP S1/1-10


USER-DEFINED FORMAT OPTIONS [top]

Display codes listed in the Search Options tables can be used to customize output. TYPE S3/TI,CC/1-5


PREDEFINED FORMAT OPTIONS [top]

NO.
 DIALOGWEB
FORMAT		 RECORD CONTENT
1 -- DIALOG Accession Number
2 -- Bibliographic Data (including Controlled Substance Section) and Category Section
3 Medium Bibliographic Data (including Controlled Substance Section)
5 Long Bibliographic Data (including Controlled Substance Section), Category Section, and Pharmacology Section
6 Free Title and Word Count
7 -- Full Record
8 Short Title, Word Count, and VA Classification
9 Full Full Record
K -- KWIC (Key Word In Context) displays a window of text; may be used alone or with other formats


DIRECT RECORD ACCESS [top]

FIELD NAME EXAMPLES
If the accession number of a specific record is known, it can be used to display the record directly. TYPE 00001091/5
DISPLAY 00000832/TI,CC
PRINT 00000964/9


Rates [top]

Rates For File: USP DI® Volume I, Drug Information for the Health Care Professional[461]
Cost per DialUnit:                 $7.80
Cost per minute:                   $2.70

Format    Types   Prints
     1    $0.00    $0.00
     2    $2.97    $2.97
     3    $2.00    $2.00
     5    $6.05    $6.05
     6    $0.00    $0.00
     7    $9.94    $9.94
     8    $0.00    $0.00
     9    $9.94    $9.94
KWIC95    $0.97       NA
KWIC96    $0.97       NA

REDIST/COPY Multiplier Table:

      Range      Multiplier
        1-2       1.00
       3-25       1.50
     26-100       3.00
    101-200       4.00
    201-500       6.00
   501-1000       8.00
 1001 or more    10.00

ARCHIVE Multiplier Table:

      Range      Multiplier
       1-25       1.50
     26-200       3.00
    201-500       6.00
   501-1000       8.00
 1001 or more    10.00
[top]


All contents Copyright © Thomson Reuters. All rights reserved.
If you have any questions about, problems with, or corrections for our Web site,
please contact Customer Service for assistance.